Small-cap stocks, with market caps between $300 million and $2 billion, present both challenges and opportunities in 2025. Evolving economic policies and rising interest rates create a complex environment for small-cap stocks, which depend more on borrowing. LiveRamp Holdings, Inc. (NYSE:RAMP) is

Olverembatinib is a new third-generation BCR-ABL inhibitor approved in China, offering hope for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients. This groundbreaking drug is included in China’s National Reimbursement Drug List, highlighting its potential to transform